BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 20451371)

  • 41. Fusion of ALK to the Ran-binding protein 2 (RANBP2) gene in inflammatory myofibroblastic tumor.
    Ma Z; Hill DA; Collins MH; Morris SW; Sumegi J; Zhou M; Zuppan C; Bridge JA
    Genes Chromosomes Cancer; 2003 May; 37(1):98-105. PubMed ID: 12661011
    [TBL] [Abstract][Full Text] [Related]  

  • 42. TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors.
    Lawrence B; Perez-Atayde A; Hibbard MK; Rubin BP; Dal Cin P; Pinkus JL; Pinkus GS; Xiao S; Yi ES; Fletcher CD; Fletcher JA
    Am J Pathol; 2000 Aug; 157(2):377-84. PubMed ID: 10934142
    [TBL] [Abstract][Full Text] [Related]  

  • 43. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.
    Choi YL; Soda M; Yamashita Y; Ueno T; Takashima J; Nakajima T; Yatabe Y; Takeuchi K; Hamada T; Haruta H; Ishikawa Y; Kimura H; Mitsudomi T; Tanio Y; Mano H;
    N Engl J Med; 2010 Oct; 363(18):1734-9. PubMed ID: 20979473
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Anaplastic lymphoma kinase-directed therapy in inflammatory myofibroblastic tumors.
    Tothova Z; Wagner AJ
    Curr Opin Oncol; 2012 Jul; 24(4):409-13. PubMed ID: 22664824
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer.
    Choi YL; Takeuchi K; Soda M; Inamura K; Togashi Y; Hatano S; Enomoto M; Hamada T; Haruta H; Watanabe H; Kurashina K; Hatanaka H; Ueno T; Takada S; Yamashita Y; Sugiyama Y; Ishikawa Y; Mano H
    Cancer Res; 2008 Jul; 68(13):4971-6. PubMed ID: 18593892
    [TBL] [Abstract][Full Text] [Related]  

  • 46. ALK gene translocations and amplifications in brain metastases of non-small cell lung cancer.
    Preusser M; Berghoff AS; Ilhan-Mutlu A; Magerle M; Dinhof C; Widhalm G; Dieckmann K; Marosi C; Wöhrer A; Hackl M; Zöchbauer-Müller S; von Deimling A; Schoppmann SF; Zielinski CC; Streubel B; Birner P
    Lung Cancer; 2013 Jun; 80(3):278-83. PubMed ID: 23453647
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Anaplastic lymphoma kinase inhibitors as anticancer therapeutics: a patent review.
    Mesaros EF; Ott GR; Dorsey BD
    Expert Opin Ther Pat; 2014 Apr; 24(4):417-42. PubMed ID: 24476492
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma with a complex karyotype and cryptic 3' ALK gene insertion to chromosome 4 q22-24.
    Stachurski D; Miron PM; Al-Homsi S; Hutchinson L; Harris NL; Woda B; Wang SA
    Hum Pathol; 2007 Jun; 38(6):940-5. PubMed ID: 17509395
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Design, synthesis, and biological activity of urea derivatives as anaplastic lymphoma kinase inhibitors.
    af Gennäs GB; Mologni L; Ahmed S; Rajaratnam M; Marin O; Lindholm N; Viltadi M; Gambacorti-Passerini C; Scapozza L; Yli-Kauhaluoma J
    ChemMedChem; 2011 Sep; 6(9):1680-92. PubMed ID: 21721129
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Small non-mucinous bronchioloalveolar carcinoma with anaplastic lymphoma kinase immunoreactivity: a novel ALK fusion gene?
    Yamamoto M; Takeuchi K; Shimoji M; Maniwa T; Isaka M; Nakagawa K; Ohde Y; Kondo H; Nakajima T
    Cancer Sci; 2012 Feb; 103(2):390-2. PubMed ID: 22296236
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Multiparametric molecular characterization of pulmonary sarcomatoid carcinoma reveals a nonrandom amplification of anaplastic lymphoma kinase (ALK) gene.
    Pelosi G; Gasparini P; Cavazza A; Rossi G; Graziano P; Barbareschi M; Perrone F; Barberis M; Takagi M; Kunimura T; Yamada T; Nakatani Y; Pastorino U; Scanagatta P; Sozzi G; Garassino M; De Braud F; Papotti M
    Lung Cancer; 2012 Sep; 77(3):507-14. PubMed ID: 22705117
    [TBL] [Abstract][Full Text] [Related]  

  • 52. ALKoma: a cancer subtype with a shared target.
    Mano H
    Cancer Discov; 2012 Jun; 2(6):495-502. PubMed ID: 22614325
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Genomic profiling of pediatric ALK-positive anaplastic large cell lymphoma: a Children's Cancer and Leukaemia Group Study.
    Youssif C; Goldenbogen J; Hamoudi R; Carreras J; Viskaduraki M; Cui YX; Bacon CM; Burke GA; Turner SD
    Genes Chromosomes Cancer; 2009 Nov; 48(11):1018-26. PubMed ID: 19691112
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion.
    Rimkunas VM; Crosby KE; Li D; Hu Y; Kelly ME; Gu TL; Mack JS; Silver MR; Zhou X; Haack H
    Clin Cancer Res; 2012 Aug; 18(16):4449-57. PubMed ID: 22661537
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Amplification but not translocation of anaplastic lymphoma kinase is a frequent event in oesophageal cancer.
    Schoppmann SF; Streubel B; Birner P
    Eur J Cancer; 2013 May; 49(8):1876-81. PubMed ID: 23490651
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Further demonstration of the diversity of chromosomal changes involving 2p23 in ALK-positive lymphoma: 2 cases expressing ALK kinase fused to CLTCL (clathrin chain polypeptide-like).
    Touriol C; Greenland C; Lamant L; Pulford K; Bernard F; Rousset T; Mason DY; Delsol G
    Blood; 2000 May; 95(10):3204-7. PubMed ID: 10807789
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The role of anaplastic lymphoma kinase inhibitors in the treatment of advanced nonsmall cell lung cancer.
    D'Arcangelo M; Wynes MW; Hirsch FR
    Curr Opin Oncol; 2013 Mar; 25(2):121-9. PubMed ID: 23385859
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Involvement of 2p23 in pulmonary inflammatory pseudotumors.
    Yousem SA; Shaw H; Cieply K
    Hum Pathol; 2001 Apr; 32(4):428-33. PubMed ID: 11331960
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.
    Soda M; Choi YL; Enomoto M; Takada S; Yamashita Y; Ishikawa S; Fujiwara S; Watanabe H; Kurashina K; Hatanaka H; Bando M; Ohno S; Ishikawa Y; Aburatani H; Niki T; Sohara Y; Sugiyama Y; Mano H
    Nature; 2007 Aug; 448(7153):561-6. PubMed ID: 17625570
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Nucleolar localization of the nucleophosmin-anaplastic lymphoma kinase is not required for malignant transformation.
    Mason DY; Pulford KA; Bischof D; Kuefer MU; Butler LH; Lamant L; Delsol G; Morris SW
    Cancer Res; 1998 Mar; 58(5):1057-62. PubMed ID: 9500471
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.